HAIXI PHARMA Reports 2025 Financial Results with Net Profit Jumping 30.09%

Stock News03-31

HAIXI PHARMA (02637) has announced its financial results for 2025. The company reported revenue of approximately 582 million yuan, representing a year-on-year increase of 24.79%. Net profit reached about 177 million yuan, up 30.09% compared to the previous year. Earnings per share were 2.55 yuan. The increase in revenue is primarily attributed to the group's enhanced marketing efforts during the year, which drove sales growth for its products Haiphone® and Anbili®. Notably, Haiphone® was newly included in the National Volume-Based Procurement (VBP) program in 2025 for the specification (5mg/20mg×14 tablets), effectively promoting expansion in hospital channels and growth in end-market sales.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1100804736?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-31 00:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100804736","market":"sg","top_or_hot":-1,"title":"HAIXI PHARMA Reports 2025 Financial Results with Net Profit Jumping 30.09%","media":"Stock News","content":"<p>HAIXI PHARMA (02637) has announced its financial results for 2025. The company reported revenue of approximately 582 million yuan, representing a year-on-year increase of 24.79%. Net profit reached about 177 million yuan, up 30.09% compared to the previous year. Earnings per share were 2.55 yuan. The increase in revenue is primarily attributed to the group's enhanced marketing efforts during the year, which drove sales growth for its products Haiphone® and Anbili®. Notably, Haiphone® was newly included in the National Volume-Based Procurement (VBP) program in 2025 for the specification (5mg/20mg×14 tablets), effectively promoting expansion in hospital channels and growth in end-market sales.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HAIXI PHARMA Reports 2025 Financial Results with Net Profit Jumping 30.09%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHAIXI PHARMA Reports 2025 Financial Results with Net Profit Jumping 30.09%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-31 00:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HAIXI PHARMA (02637) has announced its financial results for 2025. The company reported revenue of approximately 582 million yuan, representing a year-on-year increase of 24.79%. Net profit reached about 177 million yuan, up 30.09% compared to the previous year. Earnings per share were 2.55 yuan. The increase in revenue is primarily attributed to the group's enhanced marketing efforts during the year, which drove sales growth for its products Haiphone® and Anbili®. Notably, Haiphone® was newly included in the National Volume-Based Procurement (VBP) program in 2025 for the specification (5mg/20mg×14 tablets), effectively promoting expansion in hospital channels and growth in end-market sales.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02637","symbol_name":"海西新药","start_time":0,"source_url":"","article_id":"1100804736","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100804736","pubTimestamp":1774887615,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HAIXI PHARMA (02637) has announced its financial results for 2025. The company reported revenue of approximately 582 million yuan, representing a year-on-year increase of 24.79%. Net profit reached...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02637":"海西新药","BK1191":"制药"},"translate_title":"海西药业公布2025年财务业绩净利润跃升30.09%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02637":1},"content_text":"HAIXI PHARMA (02637) has announced its financial results for 2025. The company reported revenue of approximately 582 million yuan, representing a year-on-year increase of 24.79%. Net profit reached about 177 million yuan, up 30.09% compared to the previous year. Earnings per share were 2.55 yuan. The increase in revenue is primarily attributed to the group's enhanced marketing efforts during the year, which drove sales growth for its products Haiphone® and Anbili®. Notably, Haiphone® was newly included in the National Volume-Based Procurement (VBP) program in 2025 for the specification (5mg/20mg×14 tablets), effectively promoting expansion in hospital channels and growth in end-market sales.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.41.0","shortVersion":"4.41.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1100804736","isCrawlerRequest":true}